The combination of ST80 with anti-PD-L1 therapy significantly enhanced the therapeutic efficacy against TNBC tumors, effectively inhibiting tumor growth even in cases with high expression of OTUD4 and CD73. Here, OTUD4 is linked to neoplasm.